SlideShare a Scribd company logo
1 of 11
Find Industry reports, Company profiles
ReportLinker                                                                          and Market Statistics
                                               >> Get this Report Now by email!



Biogen Idec Inc. ' Product Pipeline Review ' 2012
Published on August 2012

                                                                                                               Report Summary

Biogen Idec Inc. ' Product Pipeline Review ' 2012


Summary


Global Markets Direct's pharmaceuticals report, 'Biogen Idec Inc. - Product Pipeline Review - 2012' provides data on the Biogen Idec
Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest
updates, and features on discontinued and dormant projects.


This report is built using data and information sourced from Global Markets Direct's proprietary databases, Biogen Idec Inc.'s
corporate website, SEC filings, investor presentations and featured press releases, both from Biogen Idec Inc. and industry-specific
third party sources, put together by Global Markets Direct's team.


Scope


- Biogen Idec Inc. - Brief Biogen Idec Inc. overview including business description, key information and facts, and its locations and
subsidiaries.
- Review of current pipeline of Biogen Idec Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Biogen Idec Inc. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Biogen Idec Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Biogen Idec Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Biogen Idec Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Biogen Idec Inc.'s R&D portfolio and develop key strategic initiatives to
reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Biogen Idec Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Biogen Idec Inc. and identify potential opportunities in those areas.




Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                              Page 1/11
Find Industry reports, Company profiles
ReportLinker                                                                  and Market Statistics
                                               >> Get this Report Now by email!



                                                                                             Table of Content

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Biogen Idec Inc. Snapshot 11
Biogen Idec Inc. Overview 11
Key Information 11
Key Facts 11
Biogen Idec Inc. ' Research and Development Overview 12
Key Therapeutic Areas 12
Biogen Idec Inc. ' Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products ' Monotherapy 16
Pipeline Products ' Combination Treatment Modalities 17
Biogen Idec Inc. ' Pipeline Products Glance 18
Biogen Idec Inc. ' Late Stage Pipeline 18
Registration Filed Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Biogen Idec Inc. Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Biogen Idec Inc. ' Early Stage Pipeline Products 22
Pre-Clinical Products/Combination Treatment Modalities 22
Biogen Idec Inc. ' Drug Profiles 23
Alpha Synuclein Program 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Antibodies For Amyotrophic Lateral Sclerosis 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Avonex 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BG-12 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BIIB 023 28
Product Description 28
Mechanism of Action 28
R&D Progress 28



Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                      Page 2/11
Find Industry reports, Company profiles
ReportLinker                                                                  and Market Statistics
                                               >> Get this Report Now by email!

BIIB017 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BIIB022 + Paclitaxel + Carboplatin 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BIIB022 + Sorafenib 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BIIB028 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
BIIB033 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BIIB034 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BIIB037 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BIIB050 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BIIB054 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Daclizumab HYP 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Gamma Secretase Modulator 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Long Lasting rFactor IX 42
Product Description 42
Mechanism of Action 42
R&D Progress 42



Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                      Page 3/11
Find Industry reports, Company profiles
ReportLinker                                                                  and Market Statistics
                                               >> Get this Report Now by email!

Long Lasting rFactor VIII 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Neublastin 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ocrelizumab 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Rituximab + Methotrexate + Etanercept 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Rituximab + Methotrexate + Humira 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Tau Programme 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TDP-43 Programme 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Tysabri 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Biogen Idec Inc. ' Pipeline Products by Route of Administration 56
Biogen Idec Inc. ' Pipeline Products By Mechanism of Action 57
Biogen Idec Inc. ' Recent Pipeline Updates 59
Biogen Idec Inc. - Dormant Projects 67
Biogen Idec Inc. - Discontinued Pipeline Products 69
Discontinued Pipeline Product Profiles 69
baminercept alfa 69
BG9719 69
IDEC-151 69
Vipadenant 70
Biogen Idec Inc. ' Company Statement 71
Biogen Idec Inc. ' Locations And Subsidiaries 76
Head Office 76
Other Locations & Subsidiaries 76
Biogen Idec Inc. - Key Manufacturing Facilities 80
Biogen Idec Inc., Recent Developments 81



Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                      Page 4/11
Find Industry reports, Company profiles
ReportLinker                                                                    and Market Statistics
                                               >> Get this Report Now by email!

Biogen Idec Inc.- Press Release 81
Jul 05, 2012: Biogen And Sobi Initiate Global Clinical Trial Of Hemophilia Product Candidate rFIXFc 81
Jul 05, 2012: Biogen And Sobi Initiate Global Clinical Trial Of Hemophilia Product Candidate rFVIIIFc 81
May 25, 2012: European Medicines Agency Confirms Positive Benefit-Risk Balance Of MabThera 82
May 23, 2012: Health Canada Approves Updates To TYSABRI Product Monograph To Include Anti-JC Virus Antibody Status 83
May 17, 2012: Biogen And Elan Announce Pubication Of New Analysis Of Risk Stratification For TYSABRI In New England Journal
Of Medicine 84
May 14, 2012: Biogen Idec's AVONEX Dosing Innovations For Treatment Of Multiple Sclerosis Now Available in US 86
May 09, 2012: US And EU Regulatory Authorities Accept Biogen's Oral BG-12 Marketing Applications For Review 88
Apr 26, 2012: Biogen And Elan Highlight New Data Of TYSABRI At AAN Annual Meeting 88
Apr 24, 2012: Biogen To Present Positive Phase III Results Of Oral BG-12 At AAN Annual Meeting 90
Apr 11, 2012: Biogen Idec Announces Availability Of FAMPYRA In Canada 92
Feb 28, 2012: Biogen Submits Application To FDA For Approval Of Oral BG-12 To Treat Multiple Sclerosis 93
Feb 28, 2012: FDA Approves Biogen's AVONEX PEN And Dose Titration Regimen 94
Feb 03, 2012: Acorda Presents Preclinical Data Showing Dalfampridine To Improve Motor Function In Chronic Stroke 95
Jan 26, 2012: Biogen Idec And Elan Conduct Phase IIIb Study, ASCEND To Evaluate Effectiveness Of TYSABRI As Treatment For
Secondary-Progressive Multiple Sclerosis 96
Jan 25, 2012: Health Canada Approves Roche's RITUXAN To Treat Severe Forms Of Vasculitis 97
Jan 20, 2012: FDA Updates TYSABRI Label To Include Anti-JC Virus Antibody Status As PML Risk Factor 98
Dec 09, 2009: KnoppNeurosciences Presents Phase 2 Study Results Of KNS-760704 At 20th International Symposium On ALS/MND
99
Nov 19, 2009: Tysabri, The MS Drug Doesn'T Look So Deadly Anymore 100
Oct 27, 2009: Subset Data From Two Randomized Phase 3 Trials Show Tysabri Significantly Reduces Rates Of Hospitalization In
Patients With Moderate-To-Severe Crohn'S Disease 101
Oct 19, 2009: Biogen Idec And Biovitrum Announce Decision To Advance Long-Acting Hemophilia B Therapy Into A Registrational
Trial 102
Oct 19, 2009: Elan To Highlight Tysabri Data In Crohn'S Disease At The American College Of Gastroenterology Annual Scientific
Meeting 102
Sep 14, 2009: Elan Cures Breach Of Tysabri Collaboration Agreement And Amends Terms Of Transaction With Johnson & Johnson
103
Sep 03, 2009: Elan Issues Statement Regarding Federal Court Ruling On Tysabri Collaboration Agreement 104
Sep 03, 2009: NsGene A/S Announces Neublastin Enters Phase I Clinical Trial For The Treatment Of Neuropathic Pain 104
Sep 02, 2009: Knopp Neurosciences Receives FDA Fast Track Designation For KNS-760704 In ALS 105
Aug 18, 2009: Neurimmune Therapeutics Announces Advancement Of Alzheimer's Program Into Preclinical Development 105
Aug 18, 2009: Neurimmune Therapeutics Announces Advancement Of Alzheimer's Program Into Preclinical Development 106
Aug 11, 2009: Knopp Neurosciences To Present Phase II Results Of KNS-760704 In ALS 107
Aug 06, 2009: Elan Files Declaratory Suit Against Biogen Idec Company Has Not Breached Tysabri Collaboration Agreement 108
Jul 08, 2009: Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple
Sclerosis 108
Jun 22, 2009: Biogen Idec Announces First Patient Enrolled In The Global Phase III Study Of PEGylated Interferon Beta-1a For
Relapsing Multiple Sclerosis 109
Apr 28, 2009: MRI Data Showing Tysabri Promoted Remyelination Presented At The 61St Annual Meeting Of The American
Academy Of Neurology 110
Apr 16, 2009: Biogen Idec Receives Approval For Tysabri High Titer Production 110
Mar 10, 2009: European Commission Awards Orphan Designation To KNS-760704 In ALS 111
Feb 09, 2009: MS Patients Treated With Tysabri Remain Free Of Disease Activity For Two Years, According To Data Published In
The Lancet Neurology 112
Jan 21, 2009: Biogen Researches New Therapy To Repair MS Damage 113



Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                       Page 5/11
Find Industry reports, Company profiles
ReportLinker                                                                   and Market Statistics
                                               >> Get this Report Now by email!

Apr 30, 2009: First Ten-Year Follow-Up Shows That Treatment with AVONEX Leads to Long-Term Benefits in Early Multiple Sclerosis
Patients 113
Financial Deals Landscape 115
Biogen Idec Inc., Deals Summary 115
Biogen Idec Inc., Pharmaceuticals & Healthcare, Deal Details 123
Venture Financing 123
Intellikine Raises $51 Million In Venture Financing 123
Provasculon Secures $6 Million In Series A Financing 125
GlobeImmune Secures $41.2 Million In Series C Financing 127
GlobeImmune Secures Additional $4.1 Million In Series B Financing 131
Partnerships 134
Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 134
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 136
Samsung Forms Joint Venture With Biogen Idec For Biosimilars 138
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs
140
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 142
Adimab Enters Into Co-Development Agreement With Biogen Idec 144
Amunix Enters Into Co-Development Agreement With Biogen Idec 145
Orasi Medical Enters Into An Agreement With Biogen Idec 146
Biogen Idec Amends Its Collaboration With Genentech For GA101 147
Biogen Idec Expands And Amends Collaboration With Swedish Orphan Biovitrum 149
Biogen Idec Amends Its Agreement With Facet Biotech 151
Evotec Enters Into Research Agreement With Biogen 152
Asuragen Enters Into Agreement With Biogen 153
AVEO Pharma Enters Into Co-Development Agreement With Biogen Idec 154
Dyax Expands Its Collaboration With Biogen Idec 155
Biogen Idec Enters Into Co-Development Agreement With Genentech 157
Gene Network Sciences Enters Into Collaboration Agreement With Biogen 158
Biogen Idec Enters Into Co-Development Agreement With Neurimmune Therapeutics 159
Biogen Idec Enters Into Research Collaboration Agreement With Johns Hopkins Brain Science Institute 160
LigoCyte Enters Into Co-Development Agreement With Biogen Idec 161
Biogen Idec Enters Into Agreement With Cardiokine 162
UCB Enters Into A Co-Development Agreement With Biogen 164
Biogen Idec Enters Into Agreement With Alnylam 165
Biovitrum Enters Into Co-Development Agreement With Syntonix Pharma 166
Licensing Agreements 168
MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 168
ALS Therapy Development Institute Enters Into Option For Licensing Agreement With Biogen Idec And UCB Pharma 169
Biogen Enters Into Licensing Agreement With Portola Pharma 171
Covella Pharma Amends Its Licensing Agreement With Biogen Idec 173
Biogen Idec Enters Into Licensing Agreement With Knopp Neurosciences For KNS-760704 174
NsGene Expands Licensing Agreement With Biogen Idec 176
Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 178
Trillium Therapeutics Enters Into Licensing Agreement With Biogen Idec 179
Biogen Idec Enters Into An Agreement With Acorda Therapeutics 180
Covella Pharma Enters Into Licensing Agreement With Biogen Idec 181
Biogen Idec And PDL BioPharma Form Licensing Agreement With Ophthotech 182



Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                   Page 6/11
Find Industry reports, Company profiles
ReportLinker                                                                      and Market Statistics
                                               >> Get this Report Now by email!

Biogen Idec Enters Into Licensing Agreement With Stromedix For STX-100 183
GeneGo Enters Into Licensing Agreement With Biogen 184
Merck Serono Signs An Agreement With Syntonix Pharma 185
Biogen Idec Enters Into Licensing Agreement With mondoBIOTECH 186
Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 187
Debt Offering 188
Biogen Idec Completes Public Offering Of 6.875% Senior Unsecured Notes For $550 Million 188
Biogen Idec Completes Public Offering Of 6% Senior Unsecured Notes For $450 Million 190
Asset Transactions 192
Eclipse Therapeutics Acquires Cancer Stem Cell Assets Of Biogen Idec 192
Cell Therapeutics Acquires US Rights Of Zevalin From Biogen Idec 194
Astellas Pharma Acquires AMEVIVE Rights And Assets From Biogen Idec 196
Acquisition 198
Biogen Idec To Acquire Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 198
Takeda Completes Acquisition Of Intellikine For $310 Million 201
Biogen Idec Acquires Remaining JV Stake In Biogen Dompe From Dompe 204
Biogen Idec Acquires Panima Pharma 206
Biogen Idec Sells 3.5% Stake In Facet Biotech 208
Biogen Idec Acquires Syntonix Pharma 209
Biogen Idec Acquires Fumapharm 212
Biogen Idec Acquires Conforma Therapeutics 213
Appendix 216
Methodology 216
Coverage 216
Secondary Research 216
Primary Research 216
Expert Panel Validation 216
Contact Us 217
Disclaimer 217


List of Tables


Biogen Idec Inc., Key Information 11
Biogen Idec Inc., Key Facts 11
Biogen Idec Inc. ' Pipeline by Indication, 2012 13
Biogen Idec Inc. ' Pipeline by Stage of Development, 2012 15
Biogen Idec Inc. ' Monotherapy Products in Pipeline, 2012 16
Biogen Idec Inc. ' Combination Treatment Modalities in Pipeline, 2012 17
Biogen Idec Inc. ' Filed, 2012 18
Biogen Idec Inc. ' Phase III, 2012 19
Biogen Idec Inc. ' Phase II, 2012 20
Biogen Idec Inc. ' Phase I, 2012 21
Biogen Idec Inc. ' Pre-Clinical, 2012 22
Biogen Idec Inc. ' Pipeline By Route of Administration, 2012 56
Biogen Idec Inc. ' Pipeline Products By Mechanism of Action, 2012 58
Biogen Idec Inc. ' Recent Pipeline Updates, 2012 59
Biogen Idec Inc. - Dormant Developmental Projects,2012 67
Biogen Idec Inc. - Discontinued Pipeline Products, 2012 69



Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                          Page 7/11
Find Industry reports, Company profiles
ReportLinker                                                                   and Market Statistics
                                               >> Get this Report Now by email!

Biogen Idec Inc., Other Locations 76
Biogen Idec Inc., Subsidiaries 77
Biogen Idec Inc., Key Manufacturing Facilities 80
Biogen Idec Inc., Deals Summary 115
Intellikine Raises $51 Million In Venture Financing 123
Provasculon Secures $6 Million In Series A Financing 125
GlobeImmune Secures $41.2 Million In Series C Financing 127
GlobeImmune Secures Additional $4.1 Million In Series B Financing 131
Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 134
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 136
Samsung Forms Joint Venture With Biogen Idec For Biosimilars 138
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs
140
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 142
Adimab Enters Into Co-Development Agreement With Biogen Idec 144
Amunix Enters Into Co-Development Agreement With Biogen Idec 145
Orasi Medical Enters Into An Agreement With Biogen Idec 146
Biogen Idec Amends Its Collaboration With Genentech For GA101 147
Biogen Idec Expands And Amends Collaboration With Swedish Orphan Biovitrum 149
Biogen Idec Amends Its Agreement With Facet Biotech 151
Evotec Enters Into Research Agreement With Biogen 152
Asuragen Enters Into Agreement With Biogen 153
AVEO Pharma Enters Into Co-Development Agreement With Biogen Idec 154
Dyax Expands Its Collaboration With Biogen Idec 155
Biogen Idec Enters Into Co-Development Agreement With Genentech 157
Gene Network Sciences Enters Into Collaboration Agreement With Biogen 158
Biogen Idec Enters Into Co-Development Agreement With Neurimmune Therapeutics 159
Biogen Idec Enters Into Research Collaboration Agreement With Johns Hopkins Brain Science Institute 160
LigoCyte Enters Into Co-Development Agreement With Biogen Idec 161
Biogen Idec Enters Into Agreement With Cardiokine 162
UCB Enters Into A Co-Development Agreement With Biogen 164
Biogen Idec Enters Into Agreement With Alnylam 165
Biovitrum Enters Into Co-Development Agreement With Syntonix Pharma 166
MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 168
ALS Therapy Development Institute Enters Into Option For Licensing Agreement With Biogen Idec And UCB Pharma 169
Biogen Enters Into Licensing Agreement With Portola Pharma 171
Covella Pharma Amends Its Licensing Agreement With Biogen Idec 173
Biogen Idec Enters Into Licensing Agreement With Knopp Neurosciences For KNS-760704 174
NsGene Expands Licensing Agreement With Biogen Idec 176
Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 178
Trillium Therapeutics Enters Into Licensing Agreement With Biogen Idec 179
Biogen Idec Enters Into An Agreement With Acorda Therapeutics 180
Covella Pharma Enters Into Licensing Agreement With Biogen Idec 181
Biogen Idec And PDL BioPharma Form Licensing Agreement With Ophthotech 182
Biogen Idec Enters Into Licensing Agreement With Stromedix For STX-100 183
GeneGo Enters Into Licensing Agreement With Biogen 184
Merck Serono Signs An Agreement With Syntonix Pharma 185
Biogen Idec Enters Into Licensing Agreement With mondoBIOTECH 186



Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                Page 8/11
Find Industry reports, Company profiles
ReportLinker                                                                      and Market Statistics
                                               >> Get this Report Now by email!

Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 187
Biogen Idec Completes Public Offering Of 6.875% Senior Unsecured Notes For $550 Million 188
Biogen Idec Completes Public Offering Of 6% Senior Unsecured Notes For $450 Million 190
Eclipse Therapeutics Acquires Cancer Stem Cell Assets Of Biogen Idec 192
Cell Therapeutics Acquires US Rights Of Zevalin From Biogen Idec 194
Astellas Pharma Acquires AMEVIVE Rights And Assets From Biogen Idec 196
Biogen Idec To Acquire Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 198
Takeda Completes Acquisition Of Intellikine For $310 Million 201
Biogen Idec Acquires Remaining JV Stake In Biogen Dompe From Dompe 204
Biogen Idec Acquires Panima Pharma 206
Biogen Idec Sells 3.5% Stake In Facet Biotech 208
Biogen Idec Acquires Syntonix Pharma 209
Biogen Idec Acquires Fumapharm 212
Biogen Idec Acquires Conforma Therapeutics 213


List of Figures


Biogen Idec Inc. ' Pipeline by Indication, 2012 13
Biogen Idec Inc. ' Pipeline by Stage of Development, 2012 15
Biogen Idec Inc. ' Monotherapy Products in Pipeline, 2012 16
Biogen Idec Inc. ' Combination Treatment Modalities in Pipeline, 2012 17
Biogen Idec Inc. ' Pipeline By Route of Administration, 2012 56
Biogen Idec Inc. - Pipeline Products By Mechanism of Action, 2012 57




Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                          Page 9/11
Find Industry reports, Company profiles
ReportLinker                                                                               and Market Statistics
                                               >> Get this Report Now by email!
              Fax Order Form
              To place an order via fax simply print this form, fill in the information below and fax the completed form to:
                            Europe, Middle East and Africa : + 33 4 37 37 15 56
                            Asia, Oceania and America : + 1 (805) 617 17 93
              If you have any questions please visit http://www.reportlinker.com/notify/contact


              Order Information
              Please verify that the product information is correct and select the format(s) you require.

                     Biogen Idec Inc. ' Product Pipeline Review ' 2012




              Product Formats
              Please select the product formats and the quantity you require.

                                       1 User License--USD 1 500.00               Quantity: _____



                                       Site License--USD 3 000.00                 Quantity: _____



                                       Corporate License--USD 4 500.00            Quantity: _____




              Contact Information
              Please enter all the information below in BLOCK CAPITALS


              Title:                     Mr                           Mrs   Dr              Miss            Ms                 Prof

              First Name:                     _____________________________ Last Name: __________________________________

              Email Address:                __________________________________________________________________________

              Job Title:                    __________________________________________________________________________

              Organization:                 __________________________________________________________________________

              Address:                      __________________________________________________________________________

              City:                         __________________________________________________________________________

              Postal / Zip Code:              __________________________________________________________________________

              Country:                      __________________________________________________________________________

              Phone Number:                 __________________________________________________________________________

              Fax Number:                   __________________________________________________________________________




Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                                   Page 10/11
Find Industry reports, Company profiles
ReportLinker                                                                                           and Market Statistics
                                               >> Get this Report Now by email!
              Payment Information
              Please indicate the payment method, you would like to use by selecting the appropriate box.




                      Payment by credit card                          Card Number: ______________________________________________


                                                                      Expiry Date     __________ / _________


                                                                      CVV Number _____________________


                                                                      Card Type (ex: Visa, Amex…) _________________________________




                      Payment by wire transfer                        Crédit Mutuel
                                                                      RIB : 10278 07314 00020257701 89
                                                                      BIC : CMCIFR2A
                                                                      IBAN : FR76 1027 8073 1400 0202 5770 189




                       Payment by check                               UBIQUICK SAS
                                                                      16 rue Grenette – 69002 LYON, FRANCE




                                    Customer signature:

                                     




              Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
              http://www.reportlinker.com/index/terms




                                                                       Please fax this form to:

                                                         Europe, Middle East and Africa : + 33 4 37 37 15 56

                                                           Asia, Oceania and America : + 1 (805) 617 17 93




Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                                   Page 11/11

More Related Content

More from ReportLinker.com

Global Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryGlobal Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryReportLinker.com
 
Global Wireless Gaming Industry
Global Wireless Gaming IndustryGlobal Wireless Gaming Industry
Global Wireless Gaming IndustryReportLinker.com
 
Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
 
The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
 
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
 
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
 
Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013ReportLinker.com
 
China iron ore mining industry, 2013
China iron ore mining industry, 2013China iron ore mining industry, 2013
China iron ore mining industry, 2013ReportLinker.com
 
Global Renewable Energy Report
Global Renewable Energy ReportGlobal Renewable Energy Report
Global Renewable Energy ReportReportLinker.com
 
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Inguinal Hernia Global Clinical Trials Review, H1, 2013Inguinal Hernia Global Clinical Trials Review, H1, 2013
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Cancer Cachexia Global Clinical Trials Review, H1, 2013Cancer Cachexia Global Clinical Trials Review, H1, 2013
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Pompe Disease Global Clinical Trials Review, H1, 2013
Pompe Disease Global Clinical Trials Review, H1, 2013Pompe Disease Global Clinical Trials Review, H1, 2013
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
 

More from ReportLinker.com (20)

 
 
Thisisatest
ThisisatestThisisatest
Thisisatest
 
Global Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryGlobal Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes Industry
 
Global Wireless Gaming Industry
Global Wireless Gaming IndustryGlobal Wireless Gaming Industry
Global Wireless Gaming Industry
 
Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013
 
Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013
 
The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...
 
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
 
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
 
Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013
 
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
 
China iron ore mining industry, 2013
China iron ore mining industry, 2013China iron ore mining industry, 2013
China iron ore mining industry, 2013
 
World Biomass Report
World Biomass ReportWorld Biomass Report
World Biomass Report
 
World Biofuels Report
World Biofuels ReportWorld Biofuels Report
World Biofuels Report
 
Global Renewable Energy Report
Global Renewable Energy ReportGlobal Renewable Energy Report
Global Renewable Energy Report
 
Solar PV Report
Solar PV ReportSolar PV Report
Solar PV Report
 
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Inguinal Hernia Global Clinical Trials Review, H1, 2013Inguinal Hernia Global Clinical Trials Review, H1, 2013
Inguinal Hernia Global Clinical Trials Review, H1, 2013
 
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Cancer Cachexia Global Clinical Trials Review, H1, 2013Cancer Cachexia Global Clinical Trials Review, H1, 2013
Cancer Cachexia Global Clinical Trials Review, H1, 2013
 
Pompe Disease Global Clinical Trials Review, H1, 2013
Pompe Disease Global Clinical Trials Review, H1, 2013Pompe Disease Global Clinical Trials Review, H1, 2013
Pompe Disease Global Clinical Trials Review, H1, 2013
 

Biogen Idec Inc. ' Product Pipeline Review ' 2012

  • 1. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Biogen Idec Inc. ' Product Pipeline Review ' 2012 Published on August 2012 Report Summary Biogen Idec Inc. ' Product Pipeline Review ' 2012 Summary Global Markets Direct's pharmaceuticals report, 'Biogen Idec Inc. - Product Pipeline Review - 2012' provides data on the Biogen Idec Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Biogen Idec Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Biogen Idec Inc. and industry-specific third party sources, put together by Global Markets Direct's team. Scope - Biogen Idec Inc. - Brief Biogen Idec Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Biogen Idec Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Biogen Idec Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Biogen Idec Inc.'s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Biogen Idec Inc.'s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Biogen Idec Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Biogen Idec Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Biogen Idec Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Biogen Idec Inc. and identify potential opportunities in those areas. Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/11
  • 2. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Table of Content Table of Contents Table of Contents 2 List of Tables 8 List of Figures 10 Biogen Idec Inc. Snapshot 11 Biogen Idec Inc. Overview 11 Key Information 11 Key Facts 11 Biogen Idec Inc. ' Research and Development Overview 12 Key Therapeutic Areas 12 Biogen Idec Inc. ' Pipeline Review 15 Pipeline Products by Stage of Development 15 Pipeline Products ' Monotherapy 16 Pipeline Products ' Combination Treatment Modalities 17 Biogen Idec Inc. ' Pipeline Products Glance 18 Biogen Idec Inc. ' Late Stage Pipeline 18 Registration Filed Products/Combination Treatment Modalities 18 Phase III Products/Combination Treatment Modalities 19 Biogen Idec Inc. Clinical Stage Pipeline Products 20 Phase II Products/Combination Treatment Modalities 20 Phase I Products/Combination Treatment Modalities 21 Biogen Idec Inc. ' Early Stage Pipeline Products 22 Pre-Clinical Products/Combination Treatment Modalities 22 Biogen Idec Inc. ' Drug Profiles 23 Alpha Synuclein Program 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Antibodies For Amyotrophic Lateral Sclerosis 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Avonex 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 BG-12 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 BIIB 023 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 2/11
  • 3. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! BIIB017 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BIIB022 + Paclitaxel + Carboplatin 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 BIIB022 + Sorafenib 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 BIIB028 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 BIIB033 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 BIIB034 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BIIB037 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 BIIB050 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 BIIB054 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Daclizumab HYP 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Gamma Secretase Modulator 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Long Lasting rFactor IX 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 3/11
  • 4. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Long Lasting rFactor VIII 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Neublastin 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 ocrelizumab 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Rituximab + Methotrexate + Etanercept 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Rituximab + Methotrexate + Humira 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Tau Programme 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 TDP-43 Programme 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Tysabri 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Biogen Idec Inc. ' Pipeline Products by Route of Administration 56 Biogen Idec Inc. ' Pipeline Products By Mechanism of Action 57 Biogen Idec Inc. ' Recent Pipeline Updates 59 Biogen Idec Inc. - Dormant Projects 67 Biogen Idec Inc. - Discontinued Pipeline Products 69 Discontinued Pipeline Product Profiles 69 baminercept alfa 69 BG9719 69 IDEC-151 69 Vipadenant 70 Biogen Idec Inc. ' Company Statement 71 Biogen Idec Inc. ' Locations And Subsidiaries 76 Head Office 76 Other Locations & Subsidiaries 76 Biogen Idec Inc. - Key Manufacturing Facilities 80 Biogen Idec Inc., Recent Developments 81 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 4/11
  • 5. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Biogen Idec Inc.- Press Release 81 Jul 05, 2012: Biogen And Sobi Initiate Global Clinical Trial Of Hemophilia Product Candidate rFIXFc 81 Jul 05, 2012: Biogen And Sobi Initiate Global Clinical Trial Of Hemophilia Product Candidate rFVIIIFc 81 May 25, 2012: European Medicines Agency Confirms Positive Benefit-Risk Balance Of MabThera 82 May 23, 2012: Health Canada Approves Updates To TYSABRI Product Monograph To Include Anti-JC Virus Antibody Status 83 May 17, 2012: Biogen And Elan Announce Pubication Of New Analysis Of Risk Stratification For TYSABRI In New England Journal Of Medicine 84 May 14, 2012: Biogen Idec's AVONEX Dosing Innovations For Treatment Of Multiple Sclerosis Now Available in US 86 May 09, 2012: US And EU Regulatory Authorities Accept Biogen's Oral BG-12 Marketing Applications For Review 88 Apr 26, 2012: Biogen And Elan Highlight New Data Of TYSABRI At AAN Annual Meeting 88 Apr 24, 2012: Biogen To Present Positive Phase III Results Of Oral BG-12 At AAN Annual Meeting 90 Apr 11, 2012: Biogen Idec Announces Availability Of FAMPYRA In Canada 92 Feb 28, 2012: Biogen Submits Application To FDA For Approval Of Oral BG-12 To Treat Multiple Sclerosis 93 Feb 28, 2012: FDA Approves Biogen's AVONEX PEN And Dose Titration Regimen 94 Feb 03, 2012: Acorda Presents Preclinical Data Showing Dalfampridine To Improve Motor Function In Chronic Stroke 95 Jan 26, 2012: Biogen Idec And Elan Conduct Phase IIIb Study, ASCEND To Evaluate Effectiveness Of TYSABRI As Treatment For Secondary-Progressive Multiple Sclerosis 96 Jan 25, 2012: Health Canada Approves Roche's RITUXAN To Treat Severe Forms Of Vasculitis 97 Jan 20, 2012: FDA Updates TYSABRI Label To Include Anti-JC Virus Antibody Status As PML Risk Factor 98 Dec 09, 2009: KnoppNeurosciences Presents Phase 2 Study Results Of KNS-760704 At 20th International Symposium On ALS/MND 99 Nov 19, 2009: Tysabri, The MS Drug Doesn'T Look So Deadly Anymore 100 Oct 27, 2009: Subset Data From Two Randomized Phase 3 Trials Show Tysabri Significantly Reduces Rates Of Hospitalization In Patients With Moderate-To-Severe Crohn'S Disease 101 Oct 19, 2009: Biogen Idec And Biovitrum Announce Decision To Advance Long-Acting Hemophilia B Therapy Into A Registrational Trial 102 Oct 19, 2009: Elan To Highlight Tysabri Data In Crohn'S Disease At The American College Of Gastroenterology Annual Scientific Meeting 102 Sep 14, 2009: Elan Cures Breach Of Tysabri Collaboration Agreement And Amends Terms Of Transaction With Johnson & Johnson 103 Sep 03, 2009: Elan Issues Statement Regarding Federal Court Ruling On Tysabri Collaboration Agreement 104 Sep 03, 2009: NsGene A/S Announces Neublastin Enters Phase I Clinical Trial For The Treatment Of Neuropathic Pain 104 Sep 02, 2009: Knopp Neurosciences Receives FDA Fast Track Designation For KNS-760704 In ALS 105 Aug 18, 2009: Neurimmune Therapeutics Announces Advancement Of Alzheimer's Program Into Preclinical Development 105 Aug 18, 2009: Neurimmune Therapeutics Announces Advancement Of Alzheimer's Program Into Preclinical Development 106 Aug 11, 2009: Knopp Neurosciences To Present Phase II Results Of KNS-760704 In ALS 107 Aug 06, 2009: Elan Files Declaratory Suit Against Biogen Idec Company Has Not Breached Tysabri Collaboration Agreement 108 Jul 08, 2009: Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis 108 Jun 22, 2009: Biogen Idec Announces First Patient Enrolled In The Global Phase III Study Of PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis 109 Apr 28, 2009: MRI Data Showing Tysabri Promoted Remyelination Presented At The 61St Annual Meeting Of The American Academy Of Neurology 110 Apr 16, 2009: Biogen Idec Receives Approval For Tysabri High Titer Production 110 Mar 10, 2009: European Commission Awards Orphan Designation To KNS-760704 In ALS 111 Feb 09, 2009: MS Patients Treated With Tysabri Remain Free Of Disease Activity For Two Years, According To Data Published In The Lancet Neurology 112 Jan 21, 2009: Biogen Researches New Therapy To Repair MS Damage 113 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 5/11
  • 6. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Apr 30, 2009: First Ten-Year Follow-Up Shows That Treatment with AVONEX Leads to Long-Term Benefits in Early Multiple Sclerosis Patients 113 Financial Deals Landscape 115 Biogen Idec Inc., Deals Summary 115 Biogen Idec Inc., Pharmaceuticals & Healthcare, Deal Details 123 Venture Financing 123 Intellikine Raises $51 Million In Venture Financing 123 Provasculon Secures $6 Million In Series A Financing 125 GlobeImmune Secures $41.2 Million In Series C Financing 127 GlobeImmune Secures Additional $4.1 Million In Series B Financing 131 Partnerships 134 Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 134 Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 136 Samsung Forms Joint Venture With Biogen Idec For Biosimilars 138 Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 140 Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 142 Adimab Enters Into Co-Development Agreement With Biogen Idec 144 Amunix Enters Into Co-Development Agreement With Biogen Idec 145 Orasi Medical Enters Into An Agreement With Biogen Idec 146 Biogen Idec Amends Its Collaboration With Genentech For GA101 147 Biogen Idec Expands And Amends Collaboration With Swedish Orphan Biovitrum 149 Biogen Idec Amends Its Agreement With Facet Biotech 151 Evotec Enters Into Research Agreement With Biogen 152 Asuragen Enters Into Agreement With Biogen 153 AVEO Pharma Enters Into Co-Development Agreement With Biogen Idec 154 Dyax Expands Its Collaboration With Biogen Idec 155 Biogen Idec Enters Into Co-Development Agreement With Genentech 157 Gene Network Sciences Enters Into Collaboration Agreement With Biogen 158 Biogen Idec Enters Into Co-Development Agreement With Neurimmune Therapeutics 159 Biogen Idec Enters Into Research Collaboration Agreement With Johns Hopkins Brain Science Institute 160 LigoCyte Enters Into Co-Development Agreement With Biogen Idec 161 Biogen Idec Enters Into Agreement With Cardiokine 162 UCB Enters Into A Co-Development Agreement With Biogen 164 Biogen Idec Enters Into Agreement With Alnylam 165 Biovitrum Enters Into Co-Development Agreement With Syntonix Pharma 166 Licensing Agreements 168 MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 168 ALS Therapy Development Institute Enters Into Option For Licensing Agreement With Biogen Idec And UCB Pharma 169 Biogen Enters Into Licensing Agreement With Portola Pharma 171 Covella Pharma Amends Its Licensing Agreement With Biogen Idec 173 Biogen Idec Enters Into Licensing Agreement With Knopp Neurosciences For KNS-760704 174 NsGene Expands Licensing Agreement With Biogen Idec 176 Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 178 Trillium Therapeutics Enters Into Licensing Agreement With Biogen Idec 179 Biogen Idec Enters Into An Agreement With Acorda Therapeutics 180 Covella Pharma Enters Into Licensing Agreement With Biogen Idec 181 Biogen Idec And PDL BioPharma Form Licensing Agreement With Ophthotech 182 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 6/11
  • 7. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Biogen Idec Enters Into Licensing Agreement With Stromedix For STX-100 183 GeneGo Enters Into Licensing Agreement With Biogen 184 Merck Serono Signs An Agreement With Syntonix Pharma 185 Biogen Idec Enters Into Licensing Agreement With mondoBIOTECH 186 Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 187 Debt Offering 188 Biogen Idec Completes Public Offering Of 6.875% Senior Unsecured Notes For $550 Million 188 Biogen Idec Completes Public Offering Of 6% Senior Unsecured Notes For $450 Million 190 Asset Transactions 192 Eclipse Therapeutics Acquires Cancer Stem Cell Assets Of Biogen Idec 192 Cell Therapeutics Acquires US Rights Of Zevalin From Biogen Idec 194 Astellas Pharma Acquires AMEVIVE Rights And Assets From Biogen Idec 196 Acquisition 198 Biogen Idec To Acquire Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 198 Takeda Completes Acquisition Of Intellikine For $310 Million 201 Biogen Idec Acquires Remaining JV Stake In Biogen Dompe From Dompe 204 Biogen Idec Acquires Panima Pharma 206 Biogen Idec Sells 3.5% Stake In Facet Biotech 208 Biogen Idec Acquires Syntonix Pharma 209 Biogen Idec Acquires Fumapharm 212 Biogen Idec Acquires Conforma Therapeutics 213 Appendix 216 Methodology 216 Coverage 216 Secondary Research 216 Primary Research 216 Expert Panel Validation 216 Contact Us 217 Disclaimer 217 List of Tables Biogen Idec Inc., Key Information 11 Biogen Idec Inc., Key Facts 11 Biogen Idec Inc. ' Pipeline by Indication, 2012 13 Biogen Idec Inc. ' Pipeline by Stage of Development, 2012 15 Biogen Idec Inc. ' Monotherapy Products in Pipeline, 2012 16 Biogen Idec Inc. ' Combination Treatment Modalities in Pipeline, 2012 17 Biogen Idec Inc. ' Filed, 2012 18 Biogen Idec Inc. ' Phase III, 2012 19 Biogen Idec Inc. ' Phase II, 2012 20 Biogen Idec Inc. ' Phase I, 2012 21 Biogen Idec Inc. ' Pre-Clinical, 2012 22 Biogen Idec Inc. ' Pipeline By Route of Administration, 2012 56 Biogen Idec Inc. ' Pipeline Products By Mechanism of Action, 2012 58 Biogen Idec Inc. ' Recent Pipeline Updates, 2012 59 Biogen Idec Inc. - Dormant Developmental Projects,2012 67 Biogen Idec Inc. - Discontinued Pipeline Products, 2012 69 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 7/11
  • 8. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Biogen Idec Inc., Other Locations 76 Biogen Idec Inc., Subsidiaries 77 Biogen Idec Inc., Key Manufacturing Facilities 80 Biogen Idec Inc., Deals Summary 115 Intellikine Raises $51 Million In Venture Financing 123 Provasculon Secures $6 Million In Series A Financing 125 GlobeImmune Secures $41.2 Million In Series C Financing 127 GlobeImmune Secures Additional $4.1 Million In Series B Financing 131 Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 134 Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 136 Samsung Forms Joint Venture With Biogen Idec For Biosimilars 138 Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 140 Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 142 Adimab Enters Into Co-Development Agreement With Biogen Idec 144 Amunix Enters Into Co-Development Agreement With Biogen Idec 145 Orasi Medical Enters Into An Agreement With Biogen Idec 146 Biogen Idec Amends Its Collaboration With Genentech For GA101 147 Biogen Idec Expands And Amends Collaboration With Swedish Orphan Biovitrum 149 Biogen Idec Amends Its Agreement With Facet Biotech 151 Evotec Enters Into Research Agreement With Biogen 152 Asuragen Enters Into Agreement With Biogen 153 AVEO Pharma Enters Into Co-Development Agreement With Biogen Idec 154 Dyax Expands Its Collaboration With Biogen Idec 155 Biogen Idec Enters Into Co-Development Agreement With Genentech 157 Gene Network Sciences Enters Into Collaboration Agreement With Biogen 158 Biogen Idec Enters Into Co-Development Agreement With Neurimmune Therapeutics 159 Biogen Idec Enters Into Research Collaboration Agreement With Johns Hopkins Brain Science Institute 160 LigoCyte Enters Into Co-Development Agreement With Biogen Idec 161 Biogen Idec Enters Into Agreement With Cardiokine 162 UCB Enters Into A Co-Development Agreement With Biogen 164 Biogen Idec Enters Into Agreement With Alnylam 165 Biovitrum Enters Into Co-Development Agreement With Syntonix Pharma 166 MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 168 ALS Therapy Development Institute Enters Into Option For Licensing Agreement With Biogen Idec And UCB Pharma 169 Biogen Enters Into Licensing Agreement With Portola Pharma 171 Covella Pharma Amends Its Licensing Agreement With Biogen Idec 173 Biogen Idec Enters Into Licensing Agreement With Knopp Neurosciences For KNS-760704 174 NsGene Expands Licensing Agreement With Biogen Idec 176 Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 178 Trillium Therapeutics Enters Into Licensing Agreement With Biogen Idec 179 Biogen Idec Enters Into An Agreement With Acorda Therapeutics 180 Covella Pharma Enters Into Licensing Agreement With Biogen Idec 181 Biogen Idec And PDL BioPharma Form Licensing Agreement With Ophthotech 182 Biogen Idec Enters Into Licensing Agreement With Stromedix For STX-100 183 GeneGo Enters Into Licensing Agreement With Biogen 184 Merck Serono Signs An Agreement With Syntonix Pharma 185 Biogen Idec Enters Into Licensing Agreement With mondoBIOTECH 186 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 8/11
  • 9. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 187 Biogen Idec Completes Public Offering Of 6.875% Senior Unsecured Notes For $550 Million 188 Biogen Idec Completes Public Offering Of 6% Senior Unsecured Notes For $450 Million 190 Eclipse Therapeutics Acquires Cancer Stem Cell Assets Of Biogen Idec 192 Cell Therapeutics Acquires US Rights Of Zevalin From Biogen Idec 194 Astellas Pharma Acquires AMEVIVE Rights And Assets From Biogen Idec 196 Biogen Idec To Acquire Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 198 Takeda Completes Acquisition Of Intellikine For $310 Million 201 Biogen Idec Acquires Remaining JV Stake In Biogen Dompe From Dompe 204 Biogen Idec Acquires Panima Pharma 206 Biogen Idec Sells 3.5% Stake In Facet Biotech 208 Biogen Idec Acquires Syntonix Pharma 209 Biogen Idec Acquires Fumapharm 212 Biogen Idec Acquires Conforma Therapeutics 213 List of Figures Biogen Idec Inc. ' Pipeline by Indication, 2012 13 Biogen Idec Inc. ' Pipeline by Stage of Development, 2012 15 Biogen Idec Inc. ' Monotherapy Products in Pipeline, 2012 16 Biogen Idec Inc. ' Combination Treatment Modalities in Pipeline, 2012 17 Biogen Idec Inc. ' Pipeline By Route of Administration, 2012 56 Biogen Idec Inc. - Pipeline Products By Mechanism of Action, 2012 57 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 9/11
  • 10. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Biogen Idec Inc. ' Product Pipeline Review ' 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 1 500.00 Quantity: _____ Site License--USD 3 000.00 Quantity: _____ Corporate License--USD 4 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________ Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 10/11
  • 11. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 Biogen Idec Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 11/11